Heart failure with preserved ejection fraction (HFpEF) is associated with myocardial remodelling including severe pro-fibrotic changes contributing to an increase in left ventricular stiffness and diastolic dysfunction. Serum C-terminal propeptide of procollagen type I (PIP) strongly correlates with the turnover of extracellular cardiac matrix proteins and fibrosis. Torasemide, but not furosemide, was described to reduce collagen type I synthesis in clinically unstable patients with heart failure with reduced ejection fraction. We evaluated whether its effect translated to HFpEF patients with type 2 diabetes mellitus (T2DM) and abnormal basal PIP levels. 
Introduction
Heart failure with preserved ejection fraction (HFpEF) accounts for 50% of heart failure (HF) cases, and its prevalence relative to HF with reduced ejection fraction (HFrEF) continues to rise.
1,2
HFpEF is associated with diastolic and systolic dysfunction due to a unique myocardial remodelling leading to preserved ejection fraction (EF) with increased filling indices.
2 -4 Many studies have suggested the importance of myocardial fibrosis to diastolic dysfunction. 5, 6 Pro-fibrotic triggers in HFpEF are associated with oxidative, haemodynamic, and metabolic stresses, known to be prominent especially under diabetic conditions. 2, 7 The measurement of various serum peptides arising from the metabolism of collagen types I and III, such as the peptide released during the processing of procollagen type I to collagen type I (the C-terminal propeptide of procollagen type I referred to as PIP), and of specific metalloproteinases may provide a non-invasive assessment of fibrosis. Clinical and experimental evidence supports that serum concentration of PIP reflects the rate of extracellular synthesis of collagen type I. 8, 9 Serum PIP levels have been found to be strongly correlated with histologically assessed myocardial collagen volume fraction (CVF) and myocardial collagen type I volume fraction in patients with hypertensive heart disease and HF.
10 -13 In addition, serum PIP levels and myocardial CVF reportedly changed in parallel in response to torasemide in patients with hypertensive heart disease and HF and in response to spironolactone in HF patients with idiopathic dilated cardiomyopathy.
12,14
Additionally, a net release of PIP from the heart into the circulation has been reported in patients with hypertensive heart disease and HF, suggesting a cardiac origin for systemic serum PIP in this condition.
11 Some studies have described further associations between serum PIP levels and outcomes or disease state.
15 -17 Type 2 diabetes mellitus (T2DM) is a major risk factor for HFpEF. Diastolic dysfunction is observed in ∼40% of patients with T2DM. Early changes in serum markers of extracellular cardiac matrix turnover, including PIP, have been described in patients with uncomplicated T2DM. 17, 18 Torasemide and furosemide are two common well established drugs for the treatment of congestion. 19, 20 Results of the TORIC study indicated the use . of torasemide to be associated with a lower mortality than furosemide in HFrEF. 21 Lower activation of the renin-angiotensin system, reduced changes in potassium, and unique non-diuretic effects including the ability to lower PIP release may have contributed to the results seen after torasemide treatment.
12,21 -23 Of note, the TORAFIC investigators previously demonstrated that torasemide failed to influence PIP levels in hypertensive HF patients with preserved and mid-range EF. 24 However, HFpEF is a heterogeneous syndrome and a 'one pill fits for all' strategy failed to date. 25 Rendering the respective populations under investigation more homogeneous and distinguishing phenotypes in HFpEF may prove pivotal to develop and tailor specific treatment strategies. 26 -28 We hypothesized that a single biomarker-driven approach could identify HFpEF patients with an increased collagen turnover (as indicated by serum PIP), and these patients could possibly benefit from torasemide in this regard. To mechanistically address this concept, we designed a Double-blind, RandOmised, two-arm Parallel group, mechanistic, proof-of-concept trial answering the question whether torasemide is superior to furosemide in reducing fibrosis manifest from serum PIP levels in a small number of T2DM HFpEF patients (DROP-PIP trial).
Methods

Participants
The DROP-PIP trial recruited adult ambulatory patients aged ≥18 years who were diagnosed with T2DM (defined as de novo diagnosis or medical history of T2DM on anti-diabetic therapy; see the Supplementary material online, Appendix S1) and HFpEF according to the European Society of Cardiology (ESC) guidelines (see the Supplementary material online, Appendix S1), 19 signs or symptoms of HF, normal or mildly abnormal left ventricular ejection fraction (LVEF), evidence of diastolic dysfunction and PIP ≥110 ng/mL or PIP ≥70 ng/mL if left atrial volume index (LAVI) was >29 mL/m 2 . Key exclusion criteria were cardiac valve disease defined as regurgitation of grade ≥ 2, chronic dialysis, significant liver disease, malignant tumours, a prior documented intolerance to torasemide, furosemide, or sulfonylureas, or known contraindications for torasemide or furosemide, especially hypovolaemia, hypokalaemia (≤3.6 mmol/L), hyponatraemia (≤135 mmol/L), women during the lactation period, pregnant, or of childbearing potential not using an effective contraceptive method, metabolic bone disease, autoimmune diseases or hyperthyroidism, a significant disorder of micturition, and any patient characteristic that may interfere with compliance with the trial protocol, such as dementia, substance abuse, history of non-compliance with prescribed medications or medical appointments.
Study flow
Patient enrollment started 1 October 2014 and ended by 21 December 2015. Pre-screening was obtained within the standard of care work-up at the Charité -Universitätsmedizin Berlin clinics. Consecutive, eligible subjects meeting inclusion/exclusion criteria were considered for the study. The investigators verified that patients met all inclusion (except for the PIP measurement) and none of the exclusion criteria. Written informed consent was provided by all patients before any study-related procedures were performed. During the screening visit, medical history of the patient as well as demographic data, physical examination to assess congestion and signs of HF, vital signs, New York Heart Association (NYHA) class evaluation, complete laboratory measurement [sodium, potassium, creatinine, N-terminal pro-B-type natriuretic peptide (NT-proBNP)], quality of life questionnaire (KCCQ), ECG and echocardiography were performed and recorded in the medical files of the patient. A blood serum sample to screen the concentration of PIP was obtained and transferred to a blinded PIP core laboratory. Patients with PIP measurements ≥110 ng/mL or ≥70 ng/mL with LAVI ≥29 mL/m 2 at screening were eligible for randomisation within the trial. Patients under concomitant treatment with loop diuretics (e.g. torasemide, furosemide) at screening were asked to stop the respective diuretic for at least five half-lives (stopped for ≥5 days) before becoming eligible for randomisation. Concomitant diuretics at the time of baseline visit and throughout the entire course of the trial were prohibited. All other concomitant medication was continued. Within one month after screening, a baseline randomisation visit was performed, all baseline assessments described above as well as baseline PIP measurements were repeated and confirmed. Patients were then randomised to treatment with torasemide 5 mg or furosemide 20 mg for a treatment duration of 9 months. A dose adjustment visit was optional after one month for patients with a blood pressure ≥140/90 mmHg, a control contact by phone after 44 days, a control visit after 5 months, a final visit for blinded PIP measurements, and secondary endpoint assessment after 9 months. For safety, we followed up the patients 2 weeks after the final visit. The last visit of the last patient was completed by 20 September 2016.
Trial design and oversight
The DROP-PIP trial was an investigator-initiated, mechanistic, single-centre, randomised, double-blind, two-arm, parallel group, therapeutic confirmatory phase III trial that aimed to determine the effects of torasemide (test medication) vs. furosemide (active control) on one marker (PIP) of cardiac fibrosis in eligible patients with HFpEF. A computer-based random numbers calculator and numbered sealed envelopes were used to allocate patients in a 1:1 ratio to treatment with torasemide 5 mg or furosemide 20 mg. Labelling and packaging of the trial medication were performed by a specialized pharmaceutical manufacturing company (NextPharma, Göttingen, Germany 28) , and registered at Eudra-CT-2013-003601-25. DROP-PIP was conducted in accordance with the principles of the Declaration of Helsinki of 1996, Good Clinical Practice guidelines, and local and national regulations. The Coordination Center for Clinical Trials Berlin was responsible for all aspects related to site monitoring, data monitoring, data entry, and data management. Qualified personnel monitored the trial, performed off-and on-site visits and assured scientific integrity. Data were entered into duplicate databases that were compared for identity to generate the final database, which was subjected to an automated internal review of expected data ranges and external spot-check monitoring. Patients, the investigator team, individuals performing the assessments, and data analysts remained blinded to the identity of treatment until after database lock; analyses were performed according to a predefined statistical analysis plan. All authors had full access to the data, and vouch for the integrity and completeness of the data and analyses. All primary data were archived according to good scientific practice guidelines and can be accessed via https://www.charite.de/forschung/gute_wissenschaftliche_praxis/ primaerdaten_speichern/.
Study drug administration and study procedures
The study medication supplied was an identically encapsulated form of the test medication and the active comparator for oral administration. Medication was made available in form of blinded torasemide 5 mg and furosemide 20 mg capsules. The investigators dispensed the study drug to the subject after the appropriate treatment allocated for the subject via randomisation and according to the protocol. Patients were supplied with the drug at specified visits during the treatment period and received sufficient supply of the study drug to last until their next scheduled visit. Each subject was given only the study drug carrying his/her number. All dispensing was documented in the case report forms (CRFs) and drug accountability logs were kept. The study procedures regarding transthoracic echocardiography for assessment of left ventricular mass, LVEF, diastolic function as well as cardiac volumes and dimensions were assessed locally in accordance with international standard by four experienced physicians and documented in the CRFs. Local laboratory (creatinine, sodium, potassium, NT-proBNP), ECG, 6-minute walk test as well as quality of life questionnaires (KCCQ) were collected according to established clinical protocols.
PIP measurements
The PIP levels in human serum were measured in a blinded manner with the commercial Microvue CICP EIA ELISA kit (Quidel, San Diego, CA, USA) according to the manufacturer's protocol in an independent blinded PIP core lab. Consensus on population specific cut-offs for PIP serum levels is lacking. Previously PIP levels of 65-70 ng/mL in patients without HF or normotensives vs. 110-115 ng/mL in hypertensive patients with non-severe fibrosis or patients with HF have been reported. 29, 30 We implemented PIP cut-offs defined as elevated (within the fourth quartile of a T2DM/HFpEF reference sample, being ≥110 ng/mL) or abnormal [within the third quartile of a T2DM/HFpEF reference sample, being <110 ng/mL and ≥70 ng/mL, the latter in combination with evidence of structural cardiac changes (LAVI >29 mL/m 2 )]. The limit of detection was 0.2 ng/mL and the lower limit of quantification 1 ng/mL.
Sample size considerations and statistical analysis
A predefined statistical analysis plan did set the change in percentage for the PIP values from baseline (V3) to 9-month follow-up (V7), the primary outcome parameter. A decrease between 20 and 25 percentage points in the torasemide group had previously been described. 19, 20 The expected mean of difference in the torasemide group (active) and in the furosemide group (control) were considered to be 10 percentage points (-5 percentage points for furosemide and -15 percentage points for torasemide in average). To detect the difference between both groups with a power of 80% and assumed standard deviation (SD) of 10, a total of 34 patients were required (17 per group). Metric data are shown as mean ± SD. Nominal or categorical data are presented with number and percentage. Statistical analyses for the primary outcome measure were executed for the intention-to-treat (ITT) population (predefined). Difference of means between active and control groups were compared by t-test (two-tailed) or Fisher's exact test where applicable. A P-value of <0.05 was considered to be significant. Secondary outcomes were analysed in the per-protocol population. A predefined sensitivity analysis to consider the influence of sex (male/female), age (years), or treatment with renin-angiotensin inhibitors (yes/no) was conducted using analysis of covariance (ANCOVA). Statistical analyses were performed using SAS software version 9.4 (SAS Institute, Cary, NC, USA).
Results
A total of 214 patients were pre-screened, 51.4% declined to participate in DROP-PIP. Out of the 104 patients undergoing full screening, 14% had elevated PIP levels (≥110 ng/mL), and 54% of patients showed abnormal serum PIP levels in the grey zone of <110 ng/mL and ≥70 ng/mL. The latter were eligible for randomisation in combination with evidence of structural cardiac changes only. As outlined in the CONSORT 2010 flow diagram, about one-third of all patients screened and evaluated for PIP levels did qualify for participating in this trial (Figure 1 ).
Baseline characteristics
DROP-PIP randomised 35 patients with HFpEF and T2DM; 43% of patients entered the trial with PIP levels ≥110 ng/mL. The baseline characteristics of the study population are shown in Table 1 . In summary, patients included presented with signs and symptoms of HF, which were attributed to the clinical picture of HFpEF. All patients were diabetic, and had been diagnosed or initially treated for T2DM for an average of >10 years at baseline. Patients were generally >50 years old (with a mean age in the late sixth decade of life). Aside from T2DM and HFpEF, both obesity and hypertension characterize this population. Mean body mass index was >34 kg/m 2 , and nearly all patients had a history of hypertension. In fact, mean years since diagnosis or initial treatment for hypertension at baseline was almost 14 years. More than 50% had previously been hospitalized for HF and 46% reported coronary artery disease . 
Safety, drop-outs and adherence
One non-cardiac death with no relation to the study drug or procedures was observed in the furosemide group. Overall, 17.1% of patients dropped out due to other causes, mainly refractory congestion requiring intensified therapy outside of the protocol ( Figure 1 ). Drug accountability logs showed therapy adherence of more than 9 out of 10 treatment days in the per-protocol population. No major safety concerns were raised in regard to study medication or conduct (see Supplementary material online, Figure S1 and Table S1 ).
Primary endpoint
DROP-PIP did not show a significant change in PIP from baseline to follow-up (P > 0.05). Neither treatment group did show the assumed treatment effects regarding percentage change from baseline to follow-up in serum PIP levels (ITT population) ( Figure 2 and Table 2 ). On average, patients treated with furosemide experienced a non-remarkable absolute increase of PIP (P > 0.05). In contrast, torasemide-treated patients showed a negligible absolute reduction of PIP (P > 0.05) in the per-protocol population ( Table 2 ). The 95% confidence intervals for the change in PIP for both treatment groups covered zero, indicating no treatment effect at all. Furthermore, the test for difference in means for PIP percentage change from baseline to 9 months resulted in no statistical significance between the treatment groups.
Treatment effect by PIP inclusion criteria
A post-hoc, descriptive, per-protocol analysis for treatment effects by PIP-based entry criteria showed percentage change in PIP from baseline to follow-up to be nominally higher in the torasemide vs. furosemide (-27.13 ± 16.15% vs. -7.48 ± 20.04%, P > 0.05) treated patients entering the trial with a PIP ≥110 ng/mL at baseline. In contrast, PIP change in the torasemide vs. furosemide (14.01 ± 23.45% vs. 13.65 ± 34.30%, P > 0.05) group was nominally comparable in patients entering the trial with PIP <110 ng/mL but ≥70 ng/mL and LAVI >29 mL/m 2 .
Secondary endpoints
Overall, we did observe haemodynamic/diuretic treatment effects of diuretic therapy on secondary endpoints (see Supplementary material online, Table S2 ). When comparing torasemide to furosemide, torasemide was not superior in improving functional capacity, echocardiographic surrogates of diastolic function, quality of life, and neuroendocrine activation (P > 0.05) (see Supplementary material online, Table S2 ).
Sensitivity analysis
Graphical sensitivity analysis suggests that sex and use of renin-angiotensin inhibitors at baseline showed no considerable effect on PIP percentage change from baseline. Age had no influence on change of PIP from baseline to follow-up in . Figure S2A-C) . A predefined sensitivity analysis (performed as multivariate analysis of covariance) on treatment group, sex (male/female), use of renin-angiotensin inhibitors at baseline (yes/no) and age (years) (see Supplementary material online, Table S3 ) did not show considerable effects on PIP change from baseline. An explorative graphical sensitivity analysis suggested an interaction of baseline PIP levels with treatment group in regard to percentage change in PIP over the course of the trial (see Supplementary material online, Figure S2D ). Univariate sensitivity 
Figure 2 Changes in C-terminal propeptide of procollagen type
I (PIP) following 9 months of furosemide or torasemide treatment in patients with heart failure with preserved ejection fraction and type 2 diabetes mellitus (intention-to-treat population). Graphs represent the mean of (A) the percentage change in PIP and (B) absolute changes in PIP (ng/mL) after 9 months of furosemide vs. torasemide treatment (n = 18 vs. n = 17).
analysis for treatment group, PIP at baseline, age, previous hospitalisation for HF, and time between baseline and final visit showed a significant interaction of baseline PIP levels with treatment group in regard to percentage change in PIP over the course of the trial. A multivariate ANCOVA performed including the most suspicious parameters was non-significant (see Supplementary material online, Table S4 ).
Discussion
DROP-PIP is the first single biomarker-driven, mechanistic trial targeting cardiac fibrosis in patients suffering from a T2DM and HFpEF phenotype. In this prospective, double-blind, randomised, two-arm, parallel-group trial, we could not ascertain the superiority of torasemide over furosemide in decreasing serum levels of PIP. This relatively small, hypothesis-generating trial hence conflicts with the evidence of other proof-of-concepts trials including non-diabetic HF patients with an EF ≤40% or ≥40%, 12, 23 but is in agreement with the results of the randomised TORAFIC trial, studying hypertensive HFpEF patients. The management of patients with HFpEF remains challenging. 31 The presentation of HFpEF is heterogeneous. Therapeutic benefit is scarce and the clinical presentation is better characterized as a syndrome, calling for tailored, phenotype-specific treatments. 26, 28 Although there are no persuasive and proven therapies for survival improvement of HFpEF patients, treatment of fluid retention is a IB recommendation in the current ESC guidelines.
19 Differences among loop diuretics for the treatment of HFpEF are of great interest, since smaller studies have suggested that torasemide, in contrast to furosemide, may have additional positive effects on collagen metabolism by reducing procollagen type I (PIP).
12 In DROP-PIP we included a representative, diabetic HFpEF group of moderately affected patients that is comparable to other recent therapeutic trials in HFpEF. 32 -34 Patients enrolled in this trial met the criteria outlined in the European consensus statement on the diagnosis of HFpEF. 35 A mean E/e' > 14 in the DROP-PIP population is in line with proposed cut-offs by the American recommendations for echocardiographic assessment of left ventricular diastolic function. 36 Co-morbidities, risk profile, and surrogate parameters of morbidity are fairly balanced in this study.
In a previously reported open-label trial in 36 chronic HF patients, López et al. 12 treated patients in NYHA functional class II-IV with either 10.6 ± 0.6 mg/day oral torasemide (n = 19) or 32.3 ± 3.2 mg/day oral furosemide (n = 17), in addition to their existing standard HF therapy for 8 months. The effect of torasemide on CVF was more intense in patients with HFpEF (final value of 4.37 ± 0.21%, P < 0.001) than in patients with HFrEF (final value of 4.81 ± 0.53%, P < 0.05). Further, in torasemide-treated patients, PIP decreased from 143 ± 7 to 111 ± 3 ng/mL (P < 0.01) in HF patients. Neither CVF nor PIP changed significantly in furosemide-treated patients. In all patients, CVF was directly correlated with PIP (P < 0.001) before and after treatment.
12 A subsequent study performed in non-diabetic patients with HF found the ratio of the active form of procollagen C-proteinase (PCP) to PCP zymogen, an index of PCP activation, decreased (P < 0.05) in torasemide-treated patients and unchanged in furosemide-treated patients. A reduction (P < 0.01) in both CVF and serum PIP was observed in torasemide-treated but not in furosemide-treated patients. Changes in PCP activation were positively correlated (P < 0.001) with changes in CVF and changes in PIP in patients receiving torasemide. 24 Overall, the DROP-PIP trial failed to ascertain the previously described superiority of torasemide over furosemide to alter PIP serum levels in a population of clinically stable T2DM and HFpEF patients. However, we cannot exclude that matrix dysregulation differs under diabetic conditions compared to non-diabetic patients with HFpEF. The enzyme PCP (or bone morphogenetic protein 1) is known to release PIP from procollagen type I. 37 It has been reported that glycosylation of PCP zymogen may alter its secretion, stability and ligand binding properties. 37 In general, the association of PCP activation with PIP suggests the reduction in serum PIP observed in non-diabetic, torasemide-treated HF patients to be related to reduced availability of active PCP by interference of torasemide with its post-translational activation. In pro-glycosylation chemical ambients (as is the case for the diabetic heart), one can hypothesize that torasemide may interact less with CL mean, confidence limit for the mean; F-T, furosemide-torasemide; ITT, intention-to-treat; PIP, C-terminal propeptide of procollagen type I; PP, per-protocol; SD, standard deviation; SE, standard error.
PCP zymogen and, as a result, its activation will not be reduced. Further, T2DM leads to glycation of matrix proteins including the formation of advanced glycation end products, thereby triggering fibrotic processes, which may not be adequately regulated by intrinsic degradation mechanisms. 38, 39 Additionally, several aspects and limitations of this small hypothesis-generating study should be highlighted and discussed.
First, the dosing of torasemide in the present study was 5 mg/day and hence lower than that evaluated by López et al.
12,24
The markedly lower doses of torasemide in DROP-PIP may have resulted in a different PIP-lowering potential and may contribute to the notion of a dose-depending effect, especially when compared to other trials employing higher doses, adding an explanation for failure to show superiority of torasemide over furosemide. Further titration of diuretic therapy in our study was limited due to hypotension, a common clinical problem in T2DM/HFpEF patients. This trial was designed to employ the anti-fibrotic effect of torasemide to affect collagen type I synthesis and turnover as measured by PIP. The dosing in DROP-PIP was sufficient to induce significant diuresis, evident from a comparable reduction of E/e' (see Supplementary material online, Table S2 ) in both groups. Since higher doses of torasemide (10-20 mg/day) did not lead to a change in PIP levels in the TORAFIC trial, 24 it is unlikely that patients in DROP-PIP were under-treated. However, we cannot exclude that the proposed anti-fibrotic effects of torasemide become relevant at higher doses, like 50 or 200 mg, under diabetic conditions. Since HFpEF patients are extremely preload-sensitive, the use of higher doses of long-acting loop diuretics may not be a realistic approach. type I. We did employ two PIP-based inclusion criteria, being (i) elevated (≥110 ng/mL) or (ii) abnormal PIP (<110 ng/mL and ≥70 ng/mL if combined with evidence of enlarged left atria). One may speculate that the two PIP-based inclusion criteria with elevated or abnormal PIP may represent different phenotypes within a diabetic HFpEF population. Interestingly, canine pacing-induced HF increased left atrial cross-sectional area is associated with increased left atrial collagen synthesis (as assessed by 14C-hydroxyproline incorporation in atrial tissue) but not deposition (as assessed by hydroxyproline content in atrial tissue). 40 On the other hand, it has been reported that a linear correlation exists between left atrial fibrosis and serum PIP (in control subjects and patients with atrial fibrillation). 41 However, the lack of association between left atrial size and serum PIP and deposition in the ventricular myocardium of HF patients in the present study suggests that atrial remodelling and ventricular collagen synthesis are not necessarily related in HF patients. 10, 13 Although aiming at a phenotype-specific treatment approach, we may have included different phenotypes indeed.
Third, previous studies have observed that a cut-off of 127 ng/mL for PIP provided 78% specificity and 75% sensitivity for predicting severe fibrosis with a relative risk of 4.80 (95% confidence interval 1. 19-19.30) in a hypertensive population. 42 Díez et al. 29 described PIP levels of 70.46 ± 24.27 ng/mL in normotensives and of 110.73 ± 24.68 ng/mL in hypertensive patients with non-severe fibrosis. González et al. 30 described PIP levels of 116.60 ± 3.52 ng/mL for HFpEF patients and 67.67 ± 4.35 ng/mL for controls. Serum PIP was described to independently predict HF episodes, readmission and death and a single serum measurement of PIP may have prognostic value in patients presenting with decompensated HF.
16
Treatment effects of torasemide had previously been described to range from a 20% to 25% PIP decrease under torasemide.
12,23
Both trials based their PIP measurements on radioimmunoassays, whereas the DROP-PIP employed a commercially available enzyme immunoassay-an assay previously endorsed and used within similar clinical trials, i.e. the TORAFIC trial. 24 In this trial, sample size and power calculation was based on an assumed treatment effect of a 15% decrease under torasemide, with a mean difference to furosemide of 10%. We encountered a 17% drop-out rate, mostly in patients experiencing refractory congestion and requiring diuretic strategies not available within the protocol. Both the ITT as well as the per-protocol analysis do not provide a clear signal or trend towards a superiority of torasemide over furosemide in this regard. Of note, in this relatively small, mechanistic and hypothesis-generating study, with only 35 randomised patients, we may still have lacked sample size and power, hence missing the treatment effect, and calling for further studies in the field.
Fourth, as outlined previously, DROP-PIP included patients with (i) increased PIP values at baseline as a surrogate of ongoing collagen type I turnover, and (ii) abnormal PIP values at baseline and LAVI ≥29 mL/m 2 , with less fibrosis and turnover of collagen type I. To allow cardiac collagen metabolism to become evident, a long-term treatment regimen over 9 months was endorsed. Overall DROP-PIP reached this aim and included patients with mean PIP levels of 116.9 ± 44.3 ng/mL, indicative of typical findings in HFpEF and in line with previous studies in the field. Yet, unbalanced PIP levels between both treatment groups at baseline showed up after unblinding as a result of randomisation bias. An unfavourable gender ratio and a different history in HF hospitalisation further complicate this. While mean baseline PIP levels in the furosemide group were increased and suggestive of fibrosis at 133.1 ± 50.5 ng/mL, PIP levels in the torasemide group were significantly lower, yet abnormal, at 99.7 ± 29.3 ng/mL. Univariate findings from a sensitivity analysis for an interaction of treatment with PIP levels at baseline suggest that torasemide and furosemide may exert different effects in certain patients with higher PIP values with a Pr > F of 0.0453. However, explorative multivariate analysis of covariance (see Supplementary material online, Appendix S1), adjusting for the most conspicuous co-variables, does not support the hypothesis of a significant contribution of baseline PIP values (and unbalanced baseline characteristics) to the presumed treatment effect. Following the 'regression to the mean' principle, lower PIP baseline values may allow for a less marked decrease in PIP under treatment. Across treatment groups, we aimed to investigate percentage change in PIP levels from baseline to follow-up, assessing changes in percentage decrease allows to measure subtler trends in biomarker trajectories, even in a setting of modest absolute serum PIP changes. Of note, we report a post-hoc analysis of therapy response in the respective per-protocol treatment groups, separating the two PIP-based inclusion criteria. We are clearly limited in sample size to perform such a post-hoc analysis. Some might argue that, in this trial, the possibility of inclusion via already manifest cardiac changes (suggested by LAVI) in combination with only moderate collagen type I turnover (represented by only abnormal PIP levels at baseline) in the torasemide group, may have mimicked the inhibition of extracellular synthesis of collagen type I and a restoration of an . Our hypothesis-generating data also allow a different view: DROP-PIP failed to ascertain a superiority of torasemide over furosemide to regress cardiac fibrosis in T2DM/HFpEF patients, regardless of baseline PIP values.
Study limitations
Some limitations have to be considered for this small, hypothesis-generating study including only 35 patients. In this mechanistic approach, we were limited by the small sample size and per cent power to detect a superiority of torasemide over furosemide. We did allow two PIP-based inclusion criteria for patients with clearly elevated vs. abnormal values if combined with structural cardiac changes, yet we did not stratify randomisation by these two pathways of inclusion, possibly including different T2DM/HFpEF phenotypes. Certain unbalanced baseline characteristics, being (i) an unfavourable gender ratio, (ii) a different history in HF hospitalisation, and (iii) different PIP serum levels appeared at baseline. Despite adjusting for these conspicuous co-variables in multivariate sensitivity analysis, both treatment groups showed no trend for the primary endpoint percentage change in PIP [see the Supplementary material online, Table S3 (predefined) and Table S4 (post-hoc)]. Aspects of design, such as the relatively small sample size, the relatively low doses of torasemide and furosemide, as well as an unfortunate drop-out rate do limit us further and may have obscured potential differences (e.g. in the incidence of hypokalaemia). The selection of PIP as a single, non-invasive biomarker endpoint may have limited us in investigating the complex issue of cardiac fibrosis. Owing to ethical considerations, we did not acquire endomyocardial biopsies, which could have been used to determine CVF, nor did we perform magnetic resonance tomography to visualize fibrosis. Given these complex limitations, a cautious interpretation of our data is advised and further studies are certainly needed.
Conclusion
In this mechanistic, single biomarker-driven trial in a relatively small number of patients with abnormal PIP levels suffering from T2DM and HFpEF, the proposed anti-fibrotic effect of torasemide seen in small unstable HFrEF and non-diabetic HFpEF populations could not be ascertained. Despite effective diuresis, both torasemide at and furosemide did not significantly change serum PIP levels. Thus, despite a reduction in surrogates of left ventricular filling pressure, we could not demonstrate the ability of torasemide to interfere with the matrix regulation in stable T2DM/HFpEF patients. Similarly, both loop diuretic drugs did not differ in the change of clinical parameters. Our data are hypothesis-generating and confirmation of our findings should be evaluated independently in the setting of T2DM and/or HFpEF in further studies. It is possible that the proposed anti-fibrotic effect of torasemide in clinically realistic doses is insufficient under diabetic HFpEF conditions. Within the limitations discussed above, the DROP-PIP trial failed to show that using altered PIP levels as a biomarker to initiate a torasemide-specific therapy to influence collagen breakdown offers a new successful approach in T2DM/HFpEF. The development of a tailored treatment strategy between the different HFpEF populations, especially under diabetic conditions, is warranted including specific diuretic and anti-fibrotic approaches, and further studies are urgently needed.
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